We added the following clinical trials to Metastatic Trial Search for September 2023. To see all clinical trials, please visit Metastatic Trial Search.
Stage IV HR-Positive Breast Cancer
- Benralizumab to Prevent Rashes During Treatment with Alpelisib for Metastatic ER+, HER2- Breast Cancer with PIK3CA Mutations
- Samuraciclib CDK7 Inhibitor with Fulvestrant Hormone Therapy for Advanced ER+, HER2- Breast Cancer with TP53 Mutations
- Samuraciclib CDK7 Inhibitor with Elacestrant Hormone Therapy for Advanced ER+, HER2- Breast Cancer with TP53 and ESR1 Mutations
- Estradiol Hormone Therapy for Postmenopausal Women with Advanced ER+ Breast Cancer
Stage IV HER2-Negative Breast Cancer
Stage IV Triple Negative Breast Cancer
- ctDNA Tests to Support Treatment Decisions for People with Metastatic Triple Negative, PD-L1 Negative Breast Cancer
- AB598 Immunotherapy for Advanced Triple Negative Breast Cancer
Other Stage IV Trials
- Tumor Samples From Surgery to Predict Response to Treatment for Brain Metastasis
- MRI and PET Scans to Predict Resistance to Radiation for People with Metastatic Breast Cancer
- SON-DP Immunotherapy for Advanced Breast Cancer
- Cryoablation for Breast Cancer
- ComboMATCH: Targeted Therapy Directed by Genetic Testing for Advanced Breast Cancer
- Single vs. Multiple Doses of Radiation with Immunotherapy for Breast Cancer with Brain Metastasis
- NT-175 TCR Immunotherapy for Advanced HLA Positive Breast Cancer with the TP53 R175H Mutation
Last Modified on September 1, 2023